Yusimry's Competitive Pricing Poses Threat to Humira in Health Market

AbbVie's blockbuster drug Humira, which has been the world's best-selling drug for many years, is now facing competition from lower-cost copycats known as biosimilars. Humira, with a list price of nearly $7,000 a month, treats various illnesses but has been protected by patents. However, disputes over patents have finally allowed nine Humira biosimilars to enter the market. Despite the availability of these lower-priced alternatives, the complex pharmaceutical system, including pharmacy benefit managers and insurance coverage, has hindered their adoption. A new biosimilar called Yusimry, priced at about $1,000 a month, is being sold by Coherus BioSciences and could potentially break through due to its significantly lower cost, potentially leading to savings for insurance plans and patients.